Gath I, Bar-On E, Rogowski Z, Bental E
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):89S-96S. doi: 10.1111/j.1365-2125.1983.tb02277.x.
Midazolam in doses of 0.21-0.46 mg/kg was given to four insomniacs for 27 days, and to a fifth insomniac for an additional 124 days, to assess its short, intermediate, long-term and long-standing efficacy. Automatic analysis of the polygraphic sleep recordings was carried out employing real-time signal processing (based on linear prediction), and an off-line sequential fuzzy clustering. Total sleep length did not vary significantly during medication, whereas other efficacy parameters such as sleep onset latency, wake time after sleep onset and number of nightly awakenings decreased significantly throughout the period of active medication. In one patient, midazolam was still effective after 151 days of administration. The ultrashort action (probably 3-4 h) of midazolam could be demonstrated by the distribution of the efficacy parameters, dividing the night into 2-h periods, by the unchanged total sleep length during medication compared with baseline and by the lack of any subjective clinical symptoms of hangover. The quantitative analysis of the signals showed that, although a decrease in the total amount of slow-wave sleep during long-term medication and withdrawal was detected, the total relative power in the delta band increased during drug administration. This was interpreted as redistribution of the delta activity during active medication. A lengthening of REM sleep was found during active medication probably attributable to intranight rebound. This was not followed by any clinical symptom of clinical REM rebound.(ABSTRACT TRUNCATED AT 250 WORDS)
将剂量为0.21 - 0.46毫克/千克的咪达唑仑给予4名失眠患者27天,并给予第5名失眠患者额外124天,以评估其短期、中期、长期和长期疗效。采用实时信号处理(基于线性预测)和离线顺序模糊聚类对多导睡眠记录进行自动分析。用药期间总睡眠时间无显著变化,而其他疗效参数如入睡潜伏期、睡眠开始后的觉醒时间和夜间觉醒次数在整个用药期间显著减少。在一名患者中,咪达唑仑在给药151天后仍有效。咪达唑仑的超短效作用(可能为3 - 4小时)可通过疗效参数分布、将夜间分为2小时时间段、用药期间与基线相比总睡眠时间不变以及缺乏任何宿醉主观临床症状来证明。信号的定量分析表明,虽然在长期用药和停药期间检测到慢波睡眠总量减少,但在给药期间δ频段的总相对功率增加。这被解释为用药期间δ活动的重新分布。在用药期间发现快速眼动睡眠延长,可能归因于夜间反弹。但这并未伴随任何快速眼动反弹的临床症状。(摘要截断于250字)